Recurrent Non-Small Cell Lung Cancer
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boehringer Ingelheimnintedanib
VyriadMV-NIS
Clinical Trials (2)
Total enrollment: 6 patients across 2 trials
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Start: Jan 2014Est. completion: Aug 20166 patients
Phase 2Completed
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
Start: Aug 2017Est. completion: Jan 2018
Phase 1Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
9m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
9m ago
Office Administrator
SystImmune
9m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
20m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
23m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
23m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space